Description: An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-106 in Subjects with Locally Advanced or Metastatic Solid Tumors
Mechanism of Action: Agonist of OX 40 (T cell co-stimulatory molecule)
Target Patient Population: Single agent Cohort for Renal Cell, , Gastric/GEJ, Urothelial, Combination with Pembrolizumab cohort for Gastric, Renal Cell, Non Small Cell Lung, Melanoma, Head & Neck and Nasopharyngeal
Study Design: Drug is given IV every 3 weeks